Cancer Immunotherapy
• Biotech
Jobs from the company:
Page 1 / 2
Next
T-knife
21-100
FTE
T-knife is a pioneering biotech company focused on developing innovative T cell receptor therapies specifically designed to target and treat various forms of cancer. By harnessing the power of the immune system, T-knife aims to provide effective solutions for patients battling cancer, contributing to advancements in oncology.
Funding
€174M
HQ City
San Francisco
Revenue Model
B2B
Employee Count
21-100
Last Funding Round
08/2021
Stage
Late
Team Growth
-22%
YoY Website Traffic Growth
-11%
